5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
US11325900B2 · kind B2 · utility
0Cited by
0References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2019 |
| Grant date | May 10, 2022 |
| Priority date | — |
| Expiry date | Jan 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel class of inhibitors of protein kinases useful in the treatment of proliferative cell diseases and conditions including cancers, and especially those characterised by over-expression of CDK8 and/or one or more aberrant CDK8 activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.